Orkambi Shows Long-term Safety, Efficacy in Children Ages 2-5

Long-term use of Orkambi (lumacaftor/ivacaftor), an approved cystic fibrosis (CF) treatment, is safe and effective for children between ages 2 and 5 with two copies of the disease-causing F508del mutation in the CFTR gene, a study reported. It draws on results from a Phase 3 open-label extension trial…

CF Awareness Film Festival Seeks Submissions

People living with cystic fibrosis (CF) are invited to participate in CF Awareness Month by submitting entries for the CF Awareness Film Festival, taking place virtually May 24–31. Supported by the Bonnell Foundation and the I See You Awards, the festival aims to highlight issues faced by…

Featured Column

How I Discovered That PTSD Was Causing My Post-transplant Struggles

PTSD, mental health, communities, stress, grateful, work, trauma, rare disease day, transplant, CF community, National Blood Donor Month, birthdays, holidays
Columnist Lara Govendo addresses an issue that several readers may relate to: post-transplant PTSD, which can wreak havoc.

Read the Column

Your CF Community

Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.